Skip to content

Study · Animal study (in vivo) · mouse · 2004

7 results

Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling.

Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, Pitzurra L, Bellocchio S, Velardi A, Rasi G, Di Francesco P, Garaci E

Blood24 Feb 2004Cited by 164 (Europe PMC)

PMID14982877 (opens in a new tab)DOI10.1182/blood-2003-11-4036 (opens in a new tab)PepBankPUB-14982877
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, the synthetic thymosin alpha‑1 activated T-helper cell 1-dependent antifungal immunity.

    In plain wordsIn mice, synthetic thymosin alpha‑1 activated an immune response against fungus.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTh1-dependent antifungal immunity in vivo
    Study

    mousen: not reported in source

    Mice, including highly susceptible mice with hematopoietic transplants
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo, the synthetic peptide activates T-helper (Th) cell 1-dependent antifungal immunity
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, the synthetic thymosin alpha‑1 accelerated myeloid cell recovery.

    In plain wordsIn mice, synthetic thymosin alpha‑1 sped up recovery of myeloid immune cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMyeloid cell recovery
    Study

    mousen: not reported in source

    Mice, including highly susceptible mice with hematopoietic transplants
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    accelerates myeloid cell recovery, and protects highly susceptible mice that received hematopoietic transplants from aspergillosis.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    Thymosin alpha‑1 protected highly susceptible mice that received hematopoietic transplants from aspergillosis.

    In plain wordsIn mice that had received transplants and were highly susceptible, thymosin alpha‑1 protected against a fungal lung infection.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseProtection from aspergillosis
    Study

    mousen: not reported in source

    Highly susceptible mice with hematopoietic transplants
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    protects highly susceptible mice that received hematopoietic transplants from aspergillosis.
  4. 04LabIn vitro (cells)Mechanism

    Thymosin alpha‑1 induced functional maturation of fungus-pulsed dendritic cells through the p38 MAPK/NF-kappaB-dependent pathway.

    In plain wordsIn cells, thymosin alpha‑1 made dendritic cells exposed to fungus mature.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseFunctional maturation of fungus-pulsed DCs
    Study

    n: not reported in source

    Fungus-pulsed dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    thymosin alpha 1, a naturally occurring thymic peptide, induces functional maturation and interleukin-12 production by fungus-pulsed DCs through the p38 mitogen-activated protein kinase/nuclear factor (NF)-kappaB-dependent pathway.
  5. 05LabIn vitro (cells)Mechanism

    Thymosin alpha‑1 induced interleukin-12 production by fungus-pulsed dendritic cells through the p38 MAPK/NF-kappaB-dependent pathway.

    In plain wordsIn cells, thymosin alpha‑1 raised interleukin-12 production by dendritic cells exposed to fungus.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-12 production by fungus-pulsed DCs
    Study

    n: not reported in source

    Fungus-pulsed dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    thymosin alpha 1, a naturally occurring thymic peptide, induces functional maturation and interleukin-12 production by fungus-pulsed DCs through the p38 mitogen-activated protein kinase/nuclear factor (NF)-kappaB-dependent pathway.
  6. 06LabIn vitro (cells)Mechanism

    Maturation and interleukin-12 production induced by thymosin alpha‑1 in fungus-pulsed dendritic cells depended on the p38 MAPK/NF-kappaB pathway.

    In plain wordsIn cells, thymosin alpha‑1 acted on dendritic cells through the p38 and NF-kappaB signalling pathway.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicablep38 MAPK/NF-kappaB pathway dependence
    Study

    n: not reported in source

    Fungus-pulsed dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    through the p38 mitogen-activated protein kinase/nuclear factor (NF)-kappaB-dependent pathway.
  7. 07LabIn vitro (cells)Mechanism

    The effect of thymosin alpha‑1 on dendritic cells occurred through the MyD88-dependent pathway, involving distinct Toll-like receptors.

    In plain wordsIn cells, thymosin alpha‑1 worked on dendritic cells through the MyD88 pathway and several Toll-like receptors.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableMyD88-dependent Toll-like receptor signaling
    Study

    n: not reported in source

    Fungus-pulsed dendritic cells
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This occurs by signaling through the myeloid differentiation factor 88-dependent pathway, involving distinct Toll-like receptors.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT06139419

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Sun Yat-sen Universityn = 11425 Jul 2023 to 30 Jun 2026

Non-small Cell Lung Cancer

Trial pageClinicalTrials.govUpdated 3 Aug 2026
CompletedPhase 2NCT03659578

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

Sun Yat-sen Universityn = 699 Aug 2018 to 30 Sept 2021

Non-small Cell Lung Cancer

Trial pageClinicalTrials.govUpdated 3 Jan 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.